News | August 13, 2021
Aurobindo Pharma buys Cronus Pharma Specialities for Rs 420 crores
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Aurobindo has one of the most enduring generics ecosystems among peers
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
The company will be holding 26% of the share capital in each of the solar power generating companies.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
The company will respond to the US FDA within the stipulated timelines
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Subscribe To Our Newsletter & Stay Updated
